Comparative Pharmacology
Head-to-head clinical analysis: PANIXINE DISPERDOSE versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANIXINE DISPERDOSE versus RESPORAL.
PANIXINE DISPERDOSE vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
2 mg orally twice daily
None Documented
None Documented
6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment).
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%.
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic